Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.59 |
| ▸ | MAOB | P27338 | 3/20 | 0.59 |
| ▸ | ACHE | P22303 | 5/20 | 0.56 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29113464 | 0.82 | ACHE (0.49) | ACHEHSP90AA1 | |
| SCHEMBL6330769 | 0.79 | ACHE (0.41) | MAOAMAOBACHEPYCR1HSP90AA1 | |
| SCHEMBL5899576 | 0.79 | ACHE (0.46) | MAOAMAOBACHEPYCR1 | |
| SCHEMBL4202026 | 0.78 | MAOA (0.66) | MAOAMAOBACHEBCHE | |
| SCHEMBL4188283 | 0.78 | MAOA (0.66) | MAOAMAOBACHEBCHE | |
| SCHEMBL6833092 | 0.78 | MAOA (0.66) | MAOAMAOBACHEBCHE | |
| SCHEMBL20034205 | 0.76 | MAOA (0.53) | MAOAMAOBACHEBCHE | |
| SCHEMBL5899524 | 0.75 | MAOA (0.62) | MAOAMAOBACHEBCHE | |
| SCHEMBL5443706 | 0.74 | MAOA (1.00) | MAOAMAOBACHEBCHE | |
| SCHEMBL4316968 | 0.74 | MAOA (1.00) | MAOAMAOBACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005084205-A2 | DIAMINO THIAZOLOINDAN DERIVATIVES AND THEIR USE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2005-09-15 | — | — | WO | disclosed |
| US-20050197365-A1 | Diamino thiazoloindan derivatives and their use | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197365-A1 | Diamino thiazoloindan derivatives and their use | RTN3, RTN4, DRD4 | MAOA 207/4885MAOB 174/4885ACHE 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.